This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Celgene & Acceleron Submit BLA for Luspatercept to the FDA
by Zacks Equity Research
Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY)
by Zacks Equity Research
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
by Zacks Equity Research
Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $46.80, moving +0.2% from the previous trading session.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
by Zacks Equity Research
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
Bristol-Myers' (BMY) Acquisition of Celgene Looks Certain
by Zacks Equity Research
Bristol-Myers' (BMY) acquisition offer for Celgene likely to get majority of shareholders' vote following support from Institutional Shareholder Services and Glass Lewis.
The Zacks Analyst Blog Highlights: Phillip Morris, Bristol-Myers, Walgreens, Sirius and Total System
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Phillip Morris, Bristol-Myers, Walgreens, Sirius and Total System
3 Big Pharma Stocks to Add to Your Portfolio This April
by Kinjel Shah
The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Top Research Reports for Phillip Morris, Bristol-Myers & Walgreens Boots
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Phillip Morris (PM), Bristol-Myers (BMY) and Walgreens Boots (WBA).
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group
by Zacks Equity Research
J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $48.36, moving +1.83% from the previous trading session.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review
by Zacks Equity Research
Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
J&J Files Application for Darzalex Label Expansion in Europe
by Zacks Equity Research
J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition
by Zacks Equity Research
The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $49.21, moving -0.78% from the previous trading session.
Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).